Vaccines for leishmaniasis: from proteome to vaccine candidates.
Schroeder, Juliane; Aebischer, Toni.
; 7 Suppl: 10-5, 2011 Jan-Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21245661
Overview of dendritic cell-based vaccine development for leishmaniasis.
The utility of rhesus monkey (Macaca mulatta) and other non-human primate models for preclinical testing of Leishmania candidate vaccines.
Nanobiotechnologic approach to a promising vaccine prototype for immunisation against leishmaniasis: a fast and effective method to incorporate GPI-anchored proteins of Leishmania amazonensis into liposomes.
Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines.
Identifying vaccine targets for anti-leishmanial vaccine development.
Lipid based delivery and immuno-stimulatory systems: Master tools to combat leishmaniasis.
Toll-like receptor signaling: a perspective to develop vaccine against leishmaniasis.
Specificity of anti-saliva immune response in mice repeatedly bitten by Phlebotomus sergenti.
Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.
Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.